Elsevier

NeuroImage

Volume 43, Issue 3, 15 November 2008, Pages 458-469
NeuroImage

Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: An MRI study of 676 AD, MCI, and normal subjects

https://doi.org/10.1016/j.neuroimage.2008.07.013Get rights and content

Abstract

In one of the largest brain MRI studies to date, we used tensor-based morphometry (TBM) to create 3D maps of structural atrophy in 676 subjects with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy elderly controls, scanned as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI). Using inverse-consistent 3D non-linear elastic image registration, we warped 676 individual brain MRI volumes to a population mean geometric template. Jacobian determinant maps were created, revealing the 3D profile of local volumetric expansion and compression. We compared the anatomical distribution of atrophy in 165 AD patients (age: 75.6 ± 7.6 years), 330 MCI subjects (74.8 ± 7.5), and 181 controls (75.9 ± 5.1). Brain atrophy in selected regions-of-interest was correlated with clinical measurements – the sum-of-boxes clinical dementia rating (CDR-SB), mini-mental state examination (MMSE), and the logical memory test scores – at voxel level followed by correction for multiple comparisons. Baseline temporal lobe atrophy correlated with current cognitive performance, future cognitive decline, and conversion from MCI to AD over the following year; it predicted future decline even in healthy subjects. Over half of the AD and MCI subjects carried the ApoE4 (apolipoprotein E4) gene, which increases risk for AD; they showed greater hippocampal and temporal lobe deficits than non-carriers. ApoE2 gene carriers – 1/6 of the normal group – showed reduced ventricular expansion, suggesting a protective effect. As an automated image analysis technique, TBM reveals 3D correlations between neuroimaging markers, genes, and future clinical changes, and is highly efficient for large-scale MRI studies.

Introduction

Alzheimer's disease (AD) is the most common form of dementia, affecting more than 5 million individuals in the U.S. alone, and over 24 million people worldwide. Although the exact time course is unknown, AD-related pathogenesis is believed to begin decades before clinical symptoms, such as memory impairment, can be detected (Price and Morris, 1999, Goldman et al., 2001, DeKosky and Marek, 2003). Several therapeutic trials now aim to resist disease progression in those with amnestic mild cognitive impairment (MCI) – usually a transitional state between normal aging and AD – in which 10–25% of subjects develop AD within 1 year (Petersen, 2000, Petersen et al., 1999, Petersen et al., 2001). As AD develops, patients suffer from progressive decline in executive function, language, affect, and other cognitive and behavioral domains. To identify factors that accelerate or resist disease progression, such as treatment, genetic factors, and their interactions, it is imperative to develop biomarkers, or quantitative imaging measures, that can (1) detect abnormal aging before neuronal loss is widespread; (2) gauge the level of structural brain degeneration in way that correlates with standard cognitive measures, and (3) predict future clinical decline, or imminent conversion from MCI to AD (Mueller et al., 2005b).

Magnetic resonance imaging (MRI) is widely used in AD studies as it can non-invasively quantify gray and white matter integrity with high reproducibility (Leow et al., 2006). MRI-based measures of cortical and hippocampal atrophy have been used in recent clinical trials (Grundman et al., 2002, Jack et al., 2003), and they have been shown to correlate with pathologically confirmed neuronal loss and with the molecular hallmarks of AD (Jack et al., 2002, Silbert et al., 2003). There is interest in which MRI-based measures can optimally predict future clinical decline, often defined as conversion to AD over a specific follow-up interval (Jack et al., 1998, Scahill et al., 2003, Apostolova et al., 2006, Fleisher et al., 2008), and which measures link best with standard cognitive assessments (Fox et al., 1999, Jack et al., 2004, Thompson and Apostolova, 2007, Ridha et al., 2008).

Statistical mapping methods have also been developed to quantify brain atrophy in 3D throughout the brain, offering a detailed perspective on the anatomical distribution of disease-related changes. Tensor-based morphometry (TBM) is one such image analysis technique that identifies regional structural differences from the gradients of the non-linear deformation fields that align, or ‘warp’, images to a common anatomical template (reviewed in Ashburner and Friston, 2003). At each voxel, a color-coded Jacobian determinant value indicates local volume excess or deficit relative to the corresponding anatomical structures in the template (Freeborough and Fox, 1998, Chung et al., 2001, Fox et al., 2001, Ashburner and Friston, 2003, Riddle et al., 2004). TBM provides a wide range of regional assessments from the voxel level to whole-brain analysis, and substructure volumes can be estimated simply by integrating Jacobian determinant values over a candidate region of interest. Since TBM requires little manual interaction, it has been recognized as a favorable technique for very large-scale brain MRI studies and as a candidate for use in clinical trials.

In this study, we related MRI-derived TBM measurements to genetic, clinical and cognitive assessments made at the time of the scan and over the following year. We examined a large sample (N = 676) to investigate genetic influences on the level of atrophy, and clinical correlations. Specifically, we were interested in correlating baseline temporal lobe atrophy, at the voxel level, with the sum-of-boxes clinical dementia rating (CDR-SB), change in CDR-SB over the following year, mini-mental state examination (MMSE), change in MMSE over the following year, the logical memory test (immediate and delayed), and conversion from MCI to AD. The goal was to determine specific regions in which atrophy predicts future decline. We also assessed ApoE gene effects on the level of atrophy, including not only the detrimental effect of the ApoE4 gene (Burggren et al., 2008, Chou et al., 2008a, Chou et al., 2008b), but also the hypothesized protective effects of the ApoE2 gene, which has been difficult to detect in small samples as its allelic frequency is relatively rare.

Section snippets

Subjects

Imaging data was analyzed from subjects scanned as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large five-year study launched in 2004 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public–private partnership. The primary goal of ADNI has been to test whether serial MRI, PET, other

3D profiles of brain atrophy

We conducted pair-wise comparisons among AD (N = 165), MCI (N = 330) and normal (N = 181) groups. From the individual Jacobian maps, we derived mean group difference maps and statistical maps based on the Z test. The 3D map comparing AD with normal controls revealed profound atrophy of the hippocampus and temporal lobes bilaterally in AD, accompanied by CSF expansion in the lateral ventricles and circular sulcus of the insula (Fig. 1a). The MCI group displayed similar patterns of atrophy as AD but to

Discussion

In one of the largest TBM studies to date, and one of the largest MRI studies of AD and MCI, we found that baseline temporal lobe atrophy (1) correlates with cognitive impairment (measured using CDR-SB, MMSE, and logical memory test scores), (2) predicts future cognitive decline (in terms of the CDR-SB), in all of the AD, MCI, and normal groups, and (3) predicts conversion from MCI to AD, over a subsequent one-year period. We found a dose-dependent association of the ApoE4 gene with greater

Author contributions

XH, AL, NP, SL, MC, AT, and PT performed the image analyses; CJ and MW contributed substantially to the image acquisition, study design, quality control, calibration and pre-processing, databasing and image analysis.

Acknowledgments

Data used in preparing this article were obtained from the Alzheimer's Disease Neuroimaging Initiative database (www.loni.ucla.edu/ADNI). Consequently, many ADNI investigators contributed to the design and implementation of ADNI or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators is available at www.loni.ucla.edu/ADNI/Collaboration/ADNI_Citation.shtml. This work was primarily funded by the ADNI (Principal Investigator:

References (100)

  • FolsteinM.F. et al.

    "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician

    J. Psychiatr. Res.

    (1975)
  • FoxN.C. et al.

    Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images

    Lancet

    (2001)
  • FreeboroughP.A. et al.

    Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans

    Comput. Methods Programs Biomed.

    (1997)
  • GoodC.D. et al.

    A voxel-based morphometric study of ageing in 465 normal adult human brains

    Neuroimage

    (2001)
  • HuaX. et al.

    3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry

    Neuroimage

    (2008)
  • JackC.R. et al.

    Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

    Neurobiol. Aging

    (2008)
  • JovicichJ. et al.

    Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data

    Neuroimage

    (2006)
  • KarasG.B. et al.

    Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease

    Neuroimage

    (2004)
  • KochunovP. et al.

    An optimized individual target brain in the Talairach coordinate system

    Neuroimage

    (2002)
  • LehtovirtaM. et al.

    How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer's disease? A review of neuroimaging studies

    Neurobiol. Aging

    (2000)
  • LemaitreH. et al.

    No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects

    Neuroimage

    (2005)
  • LeowA.D. et al.

    Longitudinal stability of MRI for mapping brain change using tensor-based morphometry

    Neuroimage

    (2006)
  • LorenzenP. et al.

    Multi-modal image set registration and atlas formation

    Med. Image Anal.

    (2006)
  • MuellerS.G. et al.

    The Alzheimer's disease neuroimaging initiative

    Neuroimaging Clin. N. Am.

    (2005)
  • MuellerS.G. et al.

    Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI)

    Alzheimers Dement

    (2005)
  • RiddleW.R. et al.

    Characterizing changes in MR images with color-coded Jacobians

    Magn. Reson. Imaging

    (2004)
  • RosesA.D. et al.

    APOE is a major susceptibility gene for Alzheimer's disease

    Curr. Opin. Biotechnol.

    (1994)
  • ShattuckD.W. et al.

    BrainSuite: an automated cortical surface identification tool

    Med. Image Anal.

    (2002)
  • StudholmeC. et al.

    A template free approach to volumetric spatial normalization of brain anatomy

    Pattern Recogn. Lett.

    (2004)
  • TohgiH. et al.

    Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon4 allele

    Neurosci. Lett.

    (1997)
  • ZannisV.I. et al.

    Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes

    J. Lipid. Res.

    (1982)
  • ApostolovaL.G. et al.

    Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps

    Arch. Neurol.

    (2006)
  • ApostolovaL.G. et al.

    Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease

    Arch. Neurol.

    (2007)
  • AshburnerJ. et al.

    Morphometry. Human Brain Function

    (2003)
  • BergL.

    Clinical Dementia Rating (CDR)

    Psychopharmacol. Bull.

    (1988)
  • BlackerD. et al.

    Neuropsychological measures in normal individuals that predict subsequent cognitive decline

    Arch. Neurol.

    (2007)
  • BozzaliM. et al.

    The contribution of voxel-based morphometry in staging patients with mild cognitive impairment

    Neurology

    (2006)
  • BraakH. et al.

    Neuropathological stageing of Alzheimer-related changes

    Acta Neuropathol. (Berl)

    (1991)
  • BullmoreE.T. et al.

    Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain

    IEEE Trans. Med. Imaging

    (1999)
  • CarmichaelO.T. et al.

    Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia

    Alzheimer Dis. Assoc. Disord.

    (2007)
  • ChenK. et al.

    Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates

    Am. J. Psychiatry

    (2007)
  • Chou, Y.Y., Leporé, N., Avedissian, C., Madsen, S.K., Hua, X., Jack Jr., C.R., Weiner, M.W., Toga, A.W., Thompson,...
  • CockrellJ.R. et al.

    Mini-mental state examination (MMSE)

    Psychopharmacol. Bull.

    (1988)
  • CollinsD.L. et al.

    Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space

    J. Comput. Assist. Tomogr.

    (1994)
  • CorderE.H. et al.

    Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

    Science

    (1993)
  • CorderE.H. et al.

    Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

    Nat. Genet.

    (1994)
  • DeKoskyS.T. et al.

    Looking backward to move forward: early detection of neurodegenerative disorders

    Science

    (2003)
  • FleisherA.S. et al.

    Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment

    Neurology

    (2008)
  • FoxN.C. et al.

    Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study

    Brain

    (1996)
  • FoxN.C. et al.

    Correlation between rates of brain atrophy and cognitive decline in AD

    Neurology

    (1999)
  • Cited by (300)

    View all citing articles on Scopus
    View full text